Lucid Diagnostics Q3 net loss $14.3M; EsoGuard test volume up 436% YoY to 1,088

Lucid Diagnostics Inc.

2023-Q3 EPS reported -$1.15 revenue$265,000

GAAP net loss attributable to common stockholders $14.3M (-$0.39/share); non-GAAP adjusted loss $10.2M (-$0.28/share).
EsoGuard test volume 1,088 in Q3 (+28% sequential, +436% YoY); EsoGuard-related revenue $0.1M.
Cash and equivalents $26.9M at Sep 30, 2022, down from $53.7M at Dec 31, 2021; committed equity facility up to $50M.
Sales team at 37, target 58 early 2023. 13 Lucid Test Centers in 11 states; 3 more by year-end.
EsoCheck production moved to Coastline International; expects 60% reduction in per-unit manufacturing cost.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lucid Diagnostics Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $14.3 million, EPS $(0.39) per common share.

Period: the three months ended September 30, 2022
Revenue: $0.1 million
Net income: approximately $14.3 million
EPS: $(0.39) per common share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $14.4 million, including stock-based compensation expenses of $3.6 million. GAAP net loss attributable to common stockholders was approximately $14.3 million, or $(0.39) per common share.

View on SEC.gov

Browse all earnings releases →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.